The SYNC-T solid tumor therapy platform is personalized and performed in situ (within the body).  It is a first-in-class therapy that uniquely combines partial oncolysis of a tumor with infusion of a multi-target biologic drug directly into the tumor. This method is designed to simultaneously address numerous immune suppression mechanisms while also being immunostimulatory. The synergistic approach can lead to T cell activation and proliferation. Patient-specific T cells can then migrate and attack tumors systemically throughout the body.